clinical trial · NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Bristol-Myers Squibb·phase3·recruiting·n = 590
Metastatic Non-small Cell Lung Cancer With MTAP DeletionBMS-986504PembrolizumabPlaceboCisplatinCarboplatinPemetrexedPaclitaxelNab-paclitaxel
brief summary
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
started
Jan 2, 2026
primary completion
Aug 12, 2031
completion
Aug 12, 2031
last updated
May 18, 2026
official title
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol